MBNL1 and myotonic dystrophy type 1: Furthermore, compounds or strategies aimed at reducing MBNL1 binding to expanded CUG repeats alleviate skeletal muscle dysfunctions in cell and animal models of DM1 (Warf et al., 2009; García-López et al., 2011; Childs-Disney et al., 2013; Cerro-Herreros et al., 2016).